GCSF ADA (granulocyte colony stimulating factor) ELISA (RUO)

SKU:BHE18300020
Overview
Click light‑blue chips for details
Sandwich ELISA for detecting anti-G-CSF antibodies (ADA) against Filgrastim and related G-CSF biologics in human research serum and plasma. Detection range 45–1440 ng/mL; assay time 2.5 h. For research use only.
Target antibodies to GCSF
Reactivity human
Detection Range 45 ng/mL -1440 ng/mL
Assay Time 2.5 hours
Sample Type(s) Serum Plasma
Assay Type Direct sandwich ELISA
Options selector
Catalog no. Size
EL-141-73196-96WELLSX1 96 wells × 1
Available Options

Select from the available variant options shown on this page. Availability and lead time can vary by option.

  • Options: Size (96 wells × 1).
  • Lead time: options listed as “In Stock at Manufacturer” typically ship in 3-5business days.
  • Storage: -20°C, 1 year; cold-chain shipment (typically with ice packs) is expected.
  • Please ensure someone is available to receive cold-chain deliveries promptly.
  • Sales terms and conditions: Please review prior to ordering.
Field Specification
Mfr No EL-141-73196
Assay Time
  • 2.5 hours
Assay Type
  • Direct sandwich ELISA
Detection Method
  • Peroxidase / OD450 
Detection Range 45 ng/mL -1440 ng/mL
Gene ID N/ap
Product Type
  • ELISA Kits
  • Biologic Drug Research Kits
Reactivity
  • human
Sample Type(s) Serum Plasma
Storage -20C, 1 year
Target antibodies to GCSF

Background

GCSF ADA (granulocyte colony stimulating factor) is a biological molecule commonly studied in life science research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.

Biological context

Researchers often monitor GCSF ADA (granulocyte colony stimulating factor) in Serum Plasma to better understand themes such as mechanistic biology studies, biomarker-focused profiling, and disease-model research. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.

Interpreting changes in measured levels

Depending on sample matrix and study design, increases or decreases in GCSF ADA (granulocyte colony stimulating factor) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, complementary pathway markers and controls appropriate to the biological model) and by keeping pre-analytical variables consistent across groups.

Why quantitative measurements are widely used

Quantitative immunoassays are widely used for measuring proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that GCSF ADA (granulocyte colony stimulating factor) participates in.

What is an anti-drug antibody (ADA) assay and why is it needed for biologic therapeutics?

Anti-drug antibodies (ADAs) are immune responses that can develop against biologic therapeutics including recombinant proteins, Fc-fusion proteins, and monoclonal antibodies. ADAs can reduce efficacy through accelerated drug clearance or target neutralization, and may also cause hypersensitivity reactions. ADA testing is required by the FDA and EMA as part of the immunogenicity risk assessment for all biologic drugs during clinical development.

What assay format does this ADA kit use?

This kit uses a bridging immunogenicity ELISA format. The drug (G-CSF or hGH) is used as both the capture and detection antigen, creating a “bridge” between two drug molecules held together by bivalent or multivalent ADAs in the sample. This format detects ADAs regardless of immunoglobulin isotype (IgG, IgM, IgA, IgE) and is the format recommended in FDA and EMA immunogenicity guidance.

How does residual drug in samples affect ADA detection?

Residual drug in samples is a major source of false-negative ADA results due to drug tolerance interference — circulating drug competes with plate-bound drug for ADA binding, masking positive results. Best practices include sampling at trough levels (just before the next dose), using acid dissociation or PEG precipitation pre-treatment to disrupt drug–ADA complexes, and validating drug tolerance limits using a drug-spike recovery experiment.

Should samples be tested in a screening + confirmatory tiered approach?

Yes — per FDA/EMA guidance, a tiered immunogenicity testing strategy is recommended: (1) Screening assay — all samples tested; positives flagged above a statistical cut-point. (2) Confirmatory assay — screen-positive samples re-tested with excess drug added to compete out ADA signal; ≥50% signal inhibition confirms ADA specificity. (3) Titer assay — for confirmed positives, serial dilution to determine ADA titer. This kit supports all three steps.

What controls should be included in each assay run?

Each assay run must include: a negative control (drug-naive serum), a low positive control (near the assay cut-point), and a high positive control. The cut-point is typically set at the 95th percentile of naïve donor signal distribution (5% false-positive rate). Runs where controls fall outside their acceptance ranges must be invalidated and repeated.

What is the storage requirement for this kit?

Store the complete kit at −20°C with a shelf life of 12 months from the manufacture date. Thaw reagents on ice prior to use. Reconstituted positive control and diluted samples should not be refrozen. Avoid exposing enzyme-conjugated reagents to direct light during preparation.

Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.

  1. Lim J et al. “Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant G-CSF, in rat and monkey models.” Scientific Reports, 2021.
  2. Gupta S et al. “Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.” Journal of Pharmaceutical and Biomedical Analysis, 2011. PMID: 21130095
Matches this product
$50 OFF
$50 Off All ELISA Kits
Limited time ELISA50
15%OFF
15% Off Cancer Antibodies
Ends Sep 30 ONCO15
10% OFF
10% OFF CELL LINES-Limited-Time Offer
Ends Sep 30 CELL10
FREE SAMPLE
Free Sample – CellTrypase Recombinant Trypsin-Like Enzyme
Limited time offer – availa... FREESAMPLE
FREE SAMPLE
Free Sample – MycoFold™ Growth Factors
Limited time offer – availa... Request Free Sample

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today

Try Celltrypse Free – Request Your Sample Today

Experience the power of Celltrypse™, c-LEcta's innovative enzyme solution for gentle and efficient cell dissociation. Request your free sample and discover a superior alternative for your cell culture workflows.

Try Celltrypse Free – Request Your Sample Today